HSIRI THERAPEUTICS

Biotech · Private

Sideromycin antibiotic conjugates—small-molecule therapeutics that link siderophores to antibiotics to target gram-negative bacteria like Pseudomonas aeruginosa and Acinetobacter baumannii

hsiritherapeutics.com →
Grants
$404K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
11
1 granted · 10 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Structural Modification of Daptomycin to Allow Anti-Pseudomonas Activity$202,150
Federal grantDepartment of Health and Human Services · Phase I · Structural Modification of Daptomycin to Allow Anti-Pseudomonas Activity$202,150
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3322DNA SEQ 2, INC.—$1.2M
3323Clasp Therapeutics——
3324Cgenetech, Inc.——
3325HSIRI THERAPEUTICS——
3326Grit Bio Inc——
3327SYNAPTEX, LLC——
3328SURFACE BIOADVANCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 11
  • Benzyl Amine-containing 5,6-HETEROAROMATIC Compounds Useful Against Mycobacterial Infectionapplication
  • A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINEapplication
  • Antibacterial Sideromycinsgranted
  • Synthetic Neoenactins And Combinations Of Neoenactins With Known Anti-fungal Agents With Enhanced Anti-fungal And Anti-dermatophyte Activityapplication
  • Benzyl Amine-containing 5,6-HETEROAROMATIC Compounds Useful Against Mycobacterial Infectionapplication
  • A Medicament For Treating Mycobacterial Infection Characterized By Combining A Cytochrome BC1 Inhibitor With Clarithromycin Or Azithromycin And Clofazimineapplication
  • Benzyl Amine-containing 5,6-HETEROAROMATIC Compounds Useful Against Mycobacterial Infectionapplication
  • MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN AND CLOFAZIMINEapplication
  • MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCINapplication
  • Cytochrome Bd Oxidase Inhibitors And Uses Thereofapplication
  • A Medicament For Treating Mycobacterial Infection Characterized By Combining A Cytochrome BC1 Inhibitor With Clarithromycin Or Azithromycinapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.